Need of Neurotechnology in Present Scenario

India’s neurotechnology sector shows promise but lacks scale. The National Brain Research Centre in Manesar and IISc’s facilities in Bengaluru have made significant advancements. Startups like Dognosis are innovating niche uses by decoding animal brain signals to detect cancer-related scents, indirectly pushing the envelope on human medical applications. Meanwhile, IIT Kanpur’s BCI-powered robotic prosthetic arm is among global frontrunners.

But these efforts collectively lack cohesion. India has no parallel to the NIH BRAIN Initiative, which invested a staggering $5 billion into advanced neuroscience research and neurotech development in the United States since its inception in 2013. While private-sector contribution exists (e.g., Infosys partnerships with research institutions), there is little in the way of national strategy or deep funding. Notably absent are regulatory frameworks for data privacy and neurorights, unlike Europe and Chile’s pioneering legislations.

The Case for Accelerating Neurotechnology in India

Proponents argue that neurotechnology is essential not only for health but for economic and strategic reasons. India’s demographic diversity is its genomic goldmine for neuroscience research – enabling tailored solutions for neurological disorders. Economically, neurotech aligns with pre-existing strengths in engineering and AI; the global market for BCIs alone is forecast to reach $5.4 billion by 2029, opening avenues for job creation and export-driven growth.

The therapeutic potential of neuroprosthetics cannot be overstated, especially for India’s growing population affected by spinal cord injuries and aging-related conditions like Alzheimer’s and Parkinson’s. Neurotech could be a cost-saving measure in a country where drugs often impose unsparing financial strain on patients. Consider depression alone: long-term medication dependency costs ₹2,000 or more per month per urban patient. Brain stimulation and BCIs have proven to reduce reliance on such treatments globally.

The Skepticism: Ethical Concerns and Regulatory Vacuum

Yet, investing in neurotechnology raises profound ethical and governance challenges. Brain-Computer Interfaces, particularly implantable versions, risk compromising autonomy and consent. Who owns neural data collected by devices? Can employers or governments use these tools for covert surveillance? India’s lack of privacy regulations comparable to the EU’s GDPR leaves users vulnerable to potential abuses of sensitive brain activity data.

Additionally, there’s skepticism around India’s ability to create regulatory clarity and infrastructure at scale. While the theoretical promise is undeniable, premature policy can lead to misplaced investments – as witnessed in India’s inconsistent efforts to regulate emerging sectors such as cryptocurrencies. Questions around cost-effective scaling linger too: how will ₹1 serve patients stuck in chronic poverty facing ₹15-lakh neuroprosthetic bills?

What the U.S. Did Right

The United States’ NIH BRAIN Initiative, launched in 2013, offers instructive lessons. With over $5 billion allocated to basic and applied neuroscience research, the initiative cultivated global-leading tools like Neuralink’s BCIs, which received FDA approval for human trials in 2024. Results are tangible: FDA-backed neuroprosthetics gave paralysed individuals the ability to maneuver robotic limbs – achievements that could soon translate beyond therapeutic uses.

Importantly, the U.S. balances innovation with regulation. The FDA supervises neurotech trials rigorously, ensuring ethically sound advances. India lacks similarly robust institutions, leaving its neurotechnology advancements fragmented across IIT labs and startups without central coordination.

Where Things Stand: A Fork in the Road

India has the expertise but suffers from neglect on three fronts: systemic investment, regulation, and public awareness. Without addressing ethical risks, BCIs and neurotechnologies could enter domains India is fundamentally unprepared to govern, from surveillance applications to enhancement debates. At the same time, underfunding neuroprosthetics and mental health advancements risks worsening the very problems neurotechnology can solve.

The choice isn’t between optimism and despair; it’s about ensuring alignment between intent and capacity. Neurotechnology ought to be listed as a priority sector under the National Biotechnology Development Strategy, with clear budget support above ₹10,000 crore annually. Until then, debates around being “future-ready” remain rhetorical.

Practice Questions for UPSC

Prelims Practice Questions

Frequently Asked Questions